Literature DB >> 6306272

Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies.

G R Pearson, B Vroman, B Chase, T Sculley, M Hummel, E Kieff.   

Abstract

Three monoclonal antibodies were produced against the Epstein-Barr virus-induced early antigen complex. These antibodies were shown to be specific for the early antigen complex by the fact that they only reacted with cells supporting a permissive or abortive Epstein-Barr virus infection and their synthesis was not affected by inhibitors of viral DNA synthesis. One monoclonal antibody, designated R3, was directed against a diffuse component of the early antigen complex since it reacted by immunofluorescence with cells fixed in acetone or methanol. The other two monoclonal antibodies, designated K8 and K9, reacted with a methanol-sensitive restricted component of this complex. The appearance of the R3 antigen in P3HR-1 superinfected Raji cells occurred approximately 4 h earlier than the antigen detected by K8. By both sodium dodecyl sulfate-polyacrylamide gel electrophoresis and radioimmunoelectrophoresis, it was determined that the R3 monoclonal antibody recognized two major polypeptides with molecular weights of approximately 50,000 to 52,000, whereas K8 and K9 precipitated a protein of approximately 85,000. The R3 monoclonal antibody also immunoprecipitated an in vitro primary translation product. It was, therefore, possible to map this product to the Epstein-Barr virus DNA BamH1 M fragment. These in vitro products were slightly smaller than the in vivo proteins, suggesting that these proteins probably undergo posttranslational modification during the virus replication cycle.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6306272      PMCID: PMC255226     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Inhibition of Epstein-Barr virus DNA synthesis and late gene expression by phosphonoacetic acid.

Authors:  W C Summers; G Klein
Journal:  J Virol       Date:  1976-04       Impact factor: 5.103

2.  Persisting oncogenic herpesvirus induced by the tumour promotor TPA.

Authors:  H zur Hausen; F J O'Neill; U K Freese; E Hecker
Journal:  Nature       Date:  1978-03-23       Impact factor: 49.962

3.  Activation of Epstein-Barr virus by 5-bromodeoxyuridine in "virus-free" human cells (complement-fixing antigen-immunofluorescence-leukocytes).

Authors:  P Gerber
Journal:  Proc Natl Acad Sci U S A       Date:  1972-01       Impact factor: 11.205

4.  Two distinct antigenic components in an Epstein-Barr virus-related early product induced by halogenated pyrimidines in non-producing human lymphoblastoid cells.

Authors:  K Sugawara; T Osato
Journal:  Nat New Biol       Date:  1973-06-13

5.  Identification of a critical period during the S phase for activation of the Epstein-Barr virus by 5-iododeoxyuridine.

Authors:  J G Derge; L M Martos; M A Tagamets; S Y Chang; M Chakrabarty
Journal:  Nat New Biol       Date:  1973-08-15

6.  Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells.

Authors:  G Henle; W Henle; G Klein
Journal:  Int J Cancer       Date:  1971-09-15       Impact factor: 7.396

7.  Appearance of Epstein-Barr virus-associated antigens in infected Raji cells.

Authors:  L Gergely; G Klein; I Ernberg
Journal:  Virology       Date:  1971-07       Impact factor: 3.616

8.  Production of antigens associated with Epstein-Barr virus in experimentally infected lymphoblastoid cell lines.

Authors:  G R Pearson; G Henle; W Henle
Journal:  J Natl Cancer Inst       Date:  1971-06       Impact factor: 13.506

9.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

10.  Differential reactivity of human serums with early antigens induced by Epstein-Barr virus.

Authors:  W Henle; G Henle; B A Zajac; G Pearson; R Waubke; M Scriba
Journal:  Science       Date:  1970-07-10       Impact factor: 47.728

View more
  73 in total

1.  The Epstein-Barr virus pol catalytic subunit physically interacts with the BBLF4-BSLF1-BBLF2/3 complex.

Authors:  K Fujii; N Yokoyama; T Kiyono; K Kuzushima; M Homma; Y Nishiyama; M Fujita; T Tsurumi
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.

Authors:  A L Lear; M Rowe; M G Kurilla; S Lee; S Henderson; E Kieff; A B Rickinson
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

3.  Amino acids in the basic domain of Epstein-Barr virus ZEBRA protein play distinct roles in DNA binding, activation of early lytic gene expression, and promotion of viral DNA replication.

Authors:  Lee Heston; Ayman El-Guindy; Jill Countryman; Charles Dela Cruz; Henri-Jacques Delecluse; George Miller
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  The Epstein-Barr virus BMRF1 gene is essential for lytic virus replication.

Authors:  Bernhard Neuhierl; Henri-Jacques Delecluse
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

5.  Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors.

Authors:  Jill K Countryman; Lyndle Gradoville; George Miller
Journal:  J Virol       Date:  2008-03-12       Impact factor: 5.103

6.  Epstein-Barr virus polymerase processivity factor enhances BALF2 promoter transcription as a coactivator for the BZLF1 immediate-early protein.

Authors:  Sanae Nakayama; Takayuki Murata; Kazutaka Murayama; Yoshihiro Yasui; Yoshitaka Sato; Ayumi Kudoh; Satoko Iwahori; Hiroki Isomura; Teru Kanda; Tatsuya Tsurumi
Journal:  J Biol Chem       Date:  2009-06-02       Impact factor: 5.157

7.  Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro.

Authors:  S Swaminathan; B Tomkinson; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

8.  Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.

Authors:  M Rowe; A L Lear; D Croom-Carter; A H Davies; A B Rickinson
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

9.  Two phenylalanines in the C-terminus of Epstein-Barr virus Rta protein reciprocally modulate its DNA binding and transactivation function.

Authors:  Lee-Wen Chen; Vineetha Raghavan; Pey-Jium Chang; Duane Shedd; Lee Heston; Henri-Jacques Delecluse; George Miller
Journal:  Virology       Date:  2009-02-15       Impact factor: 3.616

10.  Cloning and functional analysis of Kaposi's sarcoma-associated herpesvirus DNA polymerase and its processivity factor.

Authors:  K Lin; C Y Dai; R P Ricciardi
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.